STAT

Opinion: All study participants have a right to know their own results. My lab has been doing that for years

Giving study participants their individual results can drive greater public participation in research, increased support for science, and better health.

For less than $100 and a sample of spit, you can learn about your genes, your disease susceptibility, and your ethnic heritage. Wearable sensors report on your sleep patterns, your heart rate, and what air pollutants are nearby. With Detox Me Action Kit, a crowdsourced project my team recently launched, you can find out what common hormone-disrupting chemicals are in your body, including ingredients that manufacturers don’t have to disclose. Then there’s all the data in your medical record that you can now get hold of, thanks to changes in health laws.

Between the rise in direct-to-consumer products and more transparent medical care, people today have access to myriad types of data about their personal health — and they’ve come to expect it. Yet for participants in most research studies, outdated ethical standards prevent them from learning anything at all about what was found in their blood, urine, or any other tissue they donated for research.

Thousands of Americans take part in studies and clinical trials every year to support work ranging from basic laboratory science to long-term epidemiological studies

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks